Shares of Kala Pharmaceuticals, Inc. (KALA) are surging more than 100% Wednesday morning on the news that the FDA has accepted investigational new drug application for KPI-012, the company's lead product candidate for the treatment of persistent corneal epithelial defect (PCED).
The company plans to initiate Phase 2b study of KPI-012 for the treatment of PCED in the first quarter of 2023.
Additionally, following the FDA's acceptance of the IND application for KPI-012, the company received the remaining $25 million investment under the previously announced private placement financing.
KALA is at $8.66 currently. It has traded in the range of $3.54-$97.00 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.